ArticleScientific reports2020

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.

Yudong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.